Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
23/09/2026 11:28
BRIEF-Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences Sept 23 (Reuters) - Shanghai Henlius Biotech, Inc. 2696.HK:
ENTERS COLLABORATION AND LICENSE AGREEMENT WITH AMBERSTONE BIOSCIENCES
AGREEMENT COVERS WORLDWIDE RESEARCH AND COMMERCIALIZATION OF TWO T CELL ENGAGER PRODUCTS
TO PAY AMBERSTONE UPFRONT PAYMENT OF $4 MILLION
Further company coverage: 2696.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln